Urticaria in COVID-19 Patient Treated with Lopinavir/ Ritonavir
Journal of Pakistan Association of Dermatologists
; 31(4):725-730, 2021.
Article
in English
| Scopus | ID: covidwho-1695501
ABSTRACT
The unknown pneumonia was first found in Wuhan, China in December 2019. A novel corona virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated from lower respiratory tract swab in infected patient. The disease caused by this novel virus was then named as COVID-19 (Coronavirus Disease 2019). We report a male patient with urticarial lesions, varies on size and shape on the both arms and both legs and diagnosed with COVID-19 confirmed case. He was treated with powdered oral medicine containing combination of lopinavir and ritonavir. He developed urticarial lesions in three hours after administration of the drug. The lesions then dissapeared and resolved after 4 days of treatment using cetirizine. The conclusion of this case is still needed to be proven whether the urticarial lesion is related to COVID-19 or drugs used for COVID-19 therapy. © 2021 Pakistan Association of Dermatologists. All rights reserved.
Search on Google
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
Journal of Pakistan Association of Dermatologists
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS